NCT04675645 is a NA clinical trial of HU-Go app in Sickle Cell Disease, sponsored by Ann & Robert H Lurie Children's Hospital of Chicago.

Who is sponsoring NCT04675645?

NCT04675645 is sponsored by Ann & Robert H Lurie Children's Hospital of Chicago.

What drugs are being tested in NCT04675645?

Interventions in NCT04675645: HU-Go app.

What condition does NCT04675645 study?

NCT04675645 studies Sickle Cell Disease, Sickle B+ Thalassemia, Sickle Beta Zero Thalassemia, Sickle Cell Hemoglobin C.

Is NCT04675645 still recruiting?

NCT04675645 is currently completed. Last updated 29 July 2021.

Last reviewed 2021-07-29 · How we verify

NCT04675645

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Adherence to HU and HRQOL in Patients With Sickle Cell Disease: An Intervention Study Using HU-Go App

Completed NA Last updated 29 July 2021

What this trial tests

NA trial testing HU-Go app in Sickle Cell Disease in 33 participants. Completed in 11 July 2020.

Timeline

15 May 2018

Primary endpoint
11 July 2020

11 July 2020

Quick facts

Lead sponsor	Ann & Robert H Lurie Children's Hospital of Chicago
Phase	NA
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	supportive care
Enrollment	33
Start date	15 May 2018
Primary completion	11 July 2020
Estimated completion	11 July 2020
Sites	1 location across United States

Drugs / interventions tested

HU-Go app

Conditions studied

Sickle Cell Disease — all drugs for Sickle Cell Disease →
Sickle B+ Thalassemia — all drugs for Sickle B+ Thalassemia →
Sickle Beta Zero Thalassemia — all drugs for Sickle Beta Zero Thalassemia →
Sickle Cell Hemoglobin C — all drugs for Sickle Cell Hemoglobin C →

Sponsor

Ann & Robert H Lurie Children's Hospital of Chicago

Who can join

Adults 12 to 25, any sex, with Sickle Cell Disease or Sickle B+ Thalassemia. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

This project addresses three important research questions. First, adolescents and young adults (AYA) with sickle cell disease (SCD) and their parents/caregivers will be engaged to inform the (1) domains of health-related quality of life (HRQOL) most important to them, (2) frequency at which they are willing to complete them, and (3) other procedures related to the use, uptake and effect of the HU-Go app as a tool to improve hydroxyurea (HU) adherence. Second, this study seeks to utilize novel modern mobile technology using a multi-functional personalized platform to improve adherence to HU and measure HRQOL in youth with SCD, using NIH-endorsed PROMIS® measures, based on a conceptual model with predefined behavioral targets and mediators. Third, we plan to assess HRQOL changes and identify modifiable behavioral strategies that could serve as surrogates or predictors for HU adherence. This real-time feedback might empower self-directed changes in behavior that could improve adherence to HU.

Publications & conference data

2 peer-reviewed publications reference this trial (live from Europe PMC):

Hydroxyurea (hydroxycarbamide) for sickle cell disease.
Rankine-Mullings AE, Nevitt SJ. · · 2022 · cited 42× · PMID 36047926 · DOI 10.1002/14651858.cd002202.pub3
Impact of hydroxyurea dose and adherence on hematologic outcomes for children with sickle cell anemia.
Creary SE, Beeman C, Stanek J, King K, et al · · 2022 · cited 8× · PMID 35373884 · DOI 10.1002/pbc.29607

Verify or expand the search:

Other trials of HU-Go app

Trials testing the same drug.

NCT04691323 — The Longitudinal Relationship of HU Adherence to HRQOL, Barriers to Adherence and Habit in SCD. · NA · active not recruiting

Other recruiting trials for Sickle Cell Disease

Currently open trials in the same condition.

NCT07369024 — Sub-dissociative Dose Ketamine in Treatment of Vaso-occlusive Pain Event in Children and Young Adults · Phase 2 · recruiting
NCT06016634 — Alendronate for Osteonecrosis in Adults With Sickle Cell Disease · Phase 2 · recruiting
NCT06260891 — Zinc Supplementation in Sickle Cell Disease: A Precursor to the Think Zinc for Bones Trial · Phase 2 · recruiting
NCT07222475 — Writing Relaxing Beats in Adolescents Who Have Sickle Cell Disease · NA · recruiting
NCT07224360 — Safety of Anumigilimab (CSL324) in Adults With Sickle Cell Disease (SCD) · Phase 2 · recruiting

Other Ann & Robert H Lurie Children's Hospital of Chicago trials

Trials by the same sponsor.

NCT07411300 — Supporting Caregivers Following Mental Health Emergency Department Visits · NA · recruiting
NCT06986148 — Comparing Antibiotic Treatment Strategies for Children With Pneumonia in Outpatient Settings: (STAMPP) · NA · recruiting
NCT07372898 — Impact of Hospital to Home: Optimizing Preterm Infant Environment for Surgical Neonates and Their Parents (H-HOPE) · NA · recruiting
NCT07216326 — Our Voices Matter: Intervention for Depression in Youth · NA · recruiting
NCT06689943 — Pain After Strabismus Surgery · Phase 2 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04675645 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Ann & Robert H Lurie Children's Hospital of Chicago
Last refreshed: 29 July 2021

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04675645.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing